A defined minimum length of the first exon is required for the generation of spliced products from yeast actin pre-mRNA in vitro, though spliceosome assembly is independent of the first exon.
Does not impact clinical splicing decisions; leaves open whether exon length requirements extend beyond yeast in vitro models.
A defined minimum length of the first exon is required for the generation of spliced products from a synthetic yeast actin mRNA-precursor in vitro. If the first exon is 1, 2, 3 or 5 nucleotides long, only the first step of the splicing reaction can take place. A transcript starting with the first nucleotide of the intron does not get converted into any of the normally obtained splicing products or intermediates. On the other hand, spliceosome assembly does not depend on the presence of a first exon.
No takes yet. Share an insight, caveat, or question.
Duchêne et al. (1988) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: